https://www.selleckchem.com/ALK.html
The rate was moderate among patients with genitourinary (14%), female genital (13%), breast (11%), and thyroid tumors (. COVID-19 patients with cancer showed a high rate of in-hospital mortality and 1-year all-cause mortality, but the 12-month all-cause post-discharge mortality rate in survival discharged cancer COVID-19 patients was similar to that in Cancer Cohort. Comparing to COVID-19 Cohort, risk stratification showed that hematologic, nasopharyngeal, brain, digestive system, and lung tumors were high risk (44% vs 9%, P less then 0.001), whi
Like
Comment
Share
